.Neuropharmacology of Addictions and Degenerative Disorders (NEUROFAN)Organisation / Company: CEU San Pablo University, Department of Pharmacy, Faculty Laboratory of Neuropharmacology of Addictions and Degenerative Disorders (NEUROFAN)Selected candidates will be provided with special assistance for proposal writing and development.
Our University has been a beneficiary of 7 MSCA PF since 2017, including one MSCA-PF with an evaluation of 100/100 in 2021.Hosting Research Group:The NEUROFAN Group carries out all the phases needed for the identification of new biomarkers and therapeutic targets in CNS disorders such as addictive disorders or neurodegenerative diseases.
It also conducts preclinical validation of new compounds with therapeutic potential.A common mechanism in this type of pathology is neuroinflammation, which may aggravate neurodegenerative processes.
It is therefore of great interest to study the mechanisms that trigger and perpetuate neuroinflammation.
This has led the group to discover new targets in neuroinflammation and to study their pharmacological modulation as a new therapeutic strategy in multiple diseases that involve neuroinflammatory processes.Currently, the lab develops two research lines: (1) the study of neurodegeneration and neuroinflammation mechanisms in Alzheimer's disease and Parkinson's Disease and (2) the neuroimmune response to drugs of abuse and its contribution to neurotoxicity and addictive behaviors.The PI of NEUROFAN is Prof. Gonzalo Herradón.
Dr. Herradón serves currently as Dean of the School of Pharmacy of University San Pablo CEU.
In addition to Dr. Herradón, there are 6 researchers, permanent teaching/research staff, and up to 12 members, including postdocs, PhD students, and technicians.Publications:Galán-Llario et al.
Adolescent intermittent ethanol exposure decreases perineuronal nets in the hippocampus in a sex-dependent manner: Modulation through pharmacological inhibition of RPTPß/?.
Neuropharmacology, 247:109850, 2024.Fernández-Marcos et al.
Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models.
Nature Communications, 14(1):2779, 2023.Galán-Llario et al.
Receptor protein tyrosine phosphatase ß/? regulates loss of neurogenesis in the mouse hippocampus following adolescent acute ethanol exposure.
Neurotoxicology 94:98-107, 2023.Galán-Llario et al.
Inhibition of RPTPß/? reduces chronic ethanol intake in adolescent mice and modulates ethanol effects on hippocampal neurogenesis and glial responses in a sex-dependent manner.
Neuropharmacology 227:109438, 2023.Related ongoing Research projects:"Pharmacological modulation of perineuronal nets for the treatment of the effects of alcohol consumption during adolescence and the prevention of cognitive decline: Role of Receptor Protein Tyrosine Phosphatase beta/zeta".
Funding period: 01/01/2024 - 31/12/2025.
Funding Agency: Spanish Ministry of Health (PNSD2023/018)